Pulse Biosciences, Inc.
PLSE
$16.06
-$0.73-4.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 82.10% | 99.56% | 102.77% | 57.46% | 27.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.91% | 69.99% | 61.66% | 21.36% | 14.66% |
| Operating Income | -72.91% | -69.99% | -61.66% | -21.36% | -14.66% |
| Income Before Tax | -68.39% | -65.68% | -62.45% | -20.01% | -14.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.39% | -65.68% | -62.45% | -20.01% | -14.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.39% | -65.68% | -62.45% | -20.01% | -14.86% |
| EBIT | -72.91% | -69.99% | -61.66% | -21.36% | -14.66% |
| EBITDA | -75.03% | -72.17% | -63.33% | -21.98% | -15.14% |
| EPS Basic | -43.09% | -40.96% | -44.16% | -11.73% | 7.40% |
| Normalized Basic EPS | -43.17% | -41.03% | -44.06% | -11.80% | 7.44% |
| EPS Diluted | -43.09% | -40.96% | -44.16% | -11.73% | 7.40% |
| Normalized Diluted EPS | -43.17% | -41.03% | -44.06% | -11.80% | 7.44% |
| Average Basic Shares Outstanding | 17.66% | 17.51% | 12.71% | 7.39% | 24.07% |
| Average Diluted Shares Outstanding | 17.66% | 17.51% | 12.71% | 7.39% | 24.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |